全球 PARP 抑制劑癌症療法市場：已通過核准治療方法、劑量、定價、銷售和臨床試驗的見解（2031 年）

Global PARP Inhibitors Cancer Therapy Market, Approved Therapies Dosage, Price, Sales & Clinical Trials Insight 2031

出版日期: 2026年05月01日 | 出版商:

KuicK Research | 英文 330 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球 PARP 抑制劑癌症療法市場—已通過核准治療方法的劑量、定價、銷售和臨床試驗洞察（2031 年）報告結果和亮點：

全球PARP抑制劑癌症治療市場機會：到2031年超過80億美元
全球PARP抑制劑癌症治療市場成長（2021-2025年）：複合年成長率11%，絕對成長率50%
全球及區域銷售洞察，年度及季度：2020-2026 年第一季
深入了解已通過核准的PARP 抑制劑癌症療法的劑量、定價和銷售情況。
臨床試驗中PARP抑制劑癌症療法的最新進展：超過50種治療方法
全球 PARP 抑制劑癌症治療臨床試驗，按公司、適應症和階段分類。
競爭格局

PARP抑制劑的必要性及本報告的意義

全球腫瘤PARP抑制劑市場曾是小規模的細分市場，預計到2025年將成長至超過50億美元，成為成長最快的市場之一。這一市場成長主要得益於PARP抑制劑在多種癌症治療中的應用不斷擴展，以及其在精準醫療治療中的應用。 PARP抑制劑已被證實是治療HRD相關癌症的有效藥物，尤其適用於攜帶BRCA突變的卵巢、乳癌、攝護腺癌和胰臟癌。這些PARP抑制劑利用癌細胞中存在的DNA修復缺陷，因此是目前腫瘤治療策略中的關鍵工具。

截至2026年5月，全球總合七種主要的PARP抑制劑核准。其中，奧拉帕尼憑藉其較早的上市時間和不斷擴大的適應症，仍保持著主導地位，但像塞那帕尼這樣的新藥也展現出潛力，並已獲得令人鼓舞的監管核准。該市場的特點是收入集中度高、知識產權占主導地位，以及擴大採用生命週期管理技術，例如聯合治療和擴大適應症。

本報告旨在為讀者提供詳盡的市場概覽。除定價、劑量、供應、專利期限和銷售收入等商業因素外，報告還涵蓋科學、臨床和競爭格局等面向。本報告將臨床創新與現實結合，為投資者和決策者提供潛在機會領域的寶貴見解。

報告中包含對臨床試驗的深入分析

PARP抑制劑市場的關鍵特徵之一是正在進行的臨床研發項目數量眾多且種類繁多。本報告涵蓋了從I期到IV期的臨床研發工作，並清楚闡述了臨床試驗的成功可能性以及所採用的治療方法。報告從適應症、聯合治療、地理分佈和分層等多個角度分析了臨床試驗。

本報告反映的最顯著趨勢之一是聯合治療的快速普及。 PARP抑制劑與免疫療法和標靶治療的聯合應用已屢見不鮮。尤其值得一提的是，奧拉帕尼合併Pembrolizumab等聯合治療已顯示出超過60%的疾病控制率，主要針對攜帶HRD陽性突變的特定患者族群。尼拉帕尼合併Abiraterone阿比特龍和潑尼鬆的固定劑量組合藥物療法也取得了令人鼓舞的結果，尤其是在前列腺癌患者中，這引起了監管機構的關注，並凸顯了基因譜分析對於最大限度提高治療效果的重要性。

此外，值得一提的是後期研發階段的進展，包括III期臨床試驗所取得的成果。除了針對傳統腫瘤適應症的新藥試驗外，以分子標記而非腫瘤部位為重點的「非腫瘤依賴性」適應症也日益普及。這些趨勢正在擴大目標市場，並創造新的成長途徑。

引領PARP抑制劑研發的主要企業

PARP抑制劑市場的競爭特徵是老牌全球製藥公司與創新生物技術公司之間的互動。阿斯特捷利康、輝瑞、葛蘭素史克和百時美施貴寶等領先製藥公司積極參與研發，利用其在腫瘤學領域的深厚專業知識，並透過獲得更多核准和聯合治療來擴大市場覆蓋範圍。除了大型製藥企業外，區域性公司和專注於特定領域的生物技術公司也參與創新，尤其是在中國，本土研發的PARP抑制劑如帕米帕利和氟唑帕利已獲核准。

不同公司之間的合作與策略授權協議是該領域成功的關鍵支柱，因為它們可以分擔風險並加速研發進程。此類合作不僅能豐富產品線，還能創造市場成長潛力並帶來競爭優勢。

本報告包含公司簡介，概述了所涵蓋的公司、其主要關注領域以及在PARP抑制劑市場中的地位。這使讀者能夠概覽市場主要參與企業，而無需深入了解每家公司的研發管線、臨床試驗和商業性表現等細節。

PARP抑制劑的未來前景

未來，持續創新可望推動PARP抑制劑市場的發展。雖然PARP抑制劑主要用於腫瘤治療，但目前的研究正在探索其在神經系統疾病和發炎性疾病治療中的潛在應用。聯合治療在荷爾蒙依賴性癌症的治療中日益普及，例如，他拉唑帕尼合併Enzalutamide治療已顯著提高了患者的存活率。這兩個趨勢將確保PARP抑制劑市場在未來持續發展壯大。

伴隨診斷工具的應用有望透過識別同源重組缺陷患者，為患者帶來更多益處。此類診斷工具的普及將提高患者接受適當治療的機會，從而提升治療效率，並使PARP抑制劑的應用更具吸引力。

對於投資者和其他相關人員，PARP抑制劑市場兼具成熟的收入來源和巨大的成長潛力，極具吸引力。現有療法提供了穩定性，而個人化和聯合治療的創新和發展趨勢則為永續的價值創造鋪平了道路。

Global PARP Inhibitors Cancer Therapy Market Opportunity: > USD 8 Billion By 2031
Global PARP Inhibitors Cancer Therapy Market Growth 2021 - 2025: 11% CAGR & 50% Absolute Growth
Global, Regional, Annual & Quarterly Sales Insight: 2020 - Q1'2026
Approved PARP Inhibitors Cancer Therapy Dosage, Price & Sales Insight
Insight On PARP Inhibitors Cancer Therapy In Clinical Trials: > 50 Therapies
Global PARP Inhibitors Cancer Therapy Clinical Trials By Company, Indication & Phase
Competitive Landscape

Need for PARP Inhibitors & Why This Report?

The market for PARP inhibitors in the global oncology arena has evolved from a small niche market to one of the fastest-growing markets worth over US$ 5 Billion by 2025. This market growth is driven by the increased application of PARP inhibitors in a range of cancers, as well as their incorporation into the precision medicine approach for treatment. PARP inhibitors have been established as effective drugs for the management of HRD related cancers, especially BRCA mutated ovarian, breast, prostate, and pancreatic cancers. These PARP inhibitors take advantage of the DNA repair deficiencies found in these tumor cells, thus making them important tools in the current oncology treatment strategy.

Total of 7 leading PARP inhibitors have been approved worldwide by May 2026. Among these, the leading drug remains olaparib, owing to its earlier launch date and label expansion activities, whereas newer drugs like senaparib have shown potential and promising regulatory results. The market has notable characteristics, including high revenue concentration, good intellectual property positioning, and rising usage of lifecycle management techniques such as combination therapy and expanded indications.

The purpose of this report is to give readers an in-depth overview of the market. The report covers business aspects such as prices, doses, accessibility, patent life, and sales, as well as other scientific, clinical, and competitive aspects. The report links clinical innovation and reality, providing valuable insights for investors and decision-makers on areas with potential opportunities.

Clinical Trials Insight Included in Report

A key characteristic of the PARP inhibitor market is the richness and diversity of ongoing clinical development. This report maps out clinical development efforts from Phase I to Phase IV, giving a clear understanding of the probability of success and therapeutic approaches used during clinical trials. Clinical trials are analyzed from different angles, namely their indication, method of combination, geographical distribution, and stratification.

One of the most prominent patterns reflected in the report includes the quick adoption of combination treatments. The use of PARP inhibitors in conjunction with immunotherapy and targeted treatments has been observed. In particular, such combinations as olaparib + Pembrolizumab provide disease control rates above 60% in certain patient groups, mainly having HRD-positive mutations. There are promising results regarding the use of fixed-dose combinations of Niraparib + Abiraterone acetate + prednisone as well, which gained attention from the regulators in case of prostate cancer patients, highlighting the relevance of genetic profiling to maximize benefits.

Moreover, late-stage advancements, including the results obtained during Phase III clinical trials, are worth discussing. In addition to testing new drugs in classic oncological indications, the use of tumor-agnostic indications with an emphasis on molecular markers rather than tumor location is also becoming popular. Such trends lead to an increased addressable market and offer new growth paths.

Major Companies Driving PARP Inhibitors R&D

The competition in the market for PARP inhibitors can be characterized as an interplay between established global pharmaceutical companies and innovative biotech companies. Leading pharmaceutical organizations, including AstraZeneca, Pfizer, GSK, and Bristol Myers Squibb, actively engage in the research and development process by utilizing their vast expertise in oncology therapies and expanding their reach through additional approvals and combination therapy approaches. In addition to the large pharma industry players, there are regional companies and niche biotechs involved in innovations, especially in China, with local PARP inhibitors like pamiparib and fluzoparib already approved.

Collaboration between different companies and strategic licensing deals form one of the pillars of success in this sphere since they allow sharing risks and speeding up development processes. In addition to increasing pipeline depth, such collaborations provide scope for growth in markets and competitive advantage.

The report includes company profiles that give an overview of the history of each company covered in the report, their main areas of focus, and their standing in the PARP inhibitors market. Thus, readers are able to obtain a bird's-eye view of the most important players of the market without getting into the nitty-gritty of their pipeline, clinical, and commercial performance.

Future Outlook For PARP Inhibitors

In the future, there will be continuous innovations that will drive the PARP Inhibitors market. Despite being primarily used for oncology purposes, research on this subject has been evolving to find possible ways of use in treating neurological and inflammatory diseases. Combination therapy has been gaining popularity in hormone-dependent cancers; the usage of Talazoparib and Enzalutamide in tandem showed considerable improvements in prolonging patients' lives. These two trends are likely to ensure continuous development and growth in the future.

The usage of companion diagnostics tools can bring even more benefits to patients, which can be achieved through their ability to identify patients with homologous recombination deficiency. With such diagnostic tools at disposal, patients will get a higher chance of getting the right treatment, thus, increasing efficiency and making the PARP Inhibitors more attractive for usage.

For investors and other stakeholders, there is a very attractive combination of proven sources of established revenue streams and high growth potential within the PARP inhibitors market. Existing therapeutic agents offer stability, while innovations and the trend towards personalization and combinations open up avenues for sustainable value creation.

1. Research Methodology

2. Introduction to Poly (ADP-Ribose) Polymerase (PARP) Inhibitors

2.1 PARP Inhibitors As Class Of Targeted Therapeutics
2.2 Clinical & Translational Relevance Of PARP Inhibition
2.3 PARP Enzymes As Therapeutic Targets

3. Biological Functions Of PARP In Health & Disease

3.1 Role Of PARP In Normal Cellular Physiology & DNA Repair
3.2 PARP Dysregulation In Disease Pathogenesis & Genomic Instability
3.3 Mechanisms Of PARP Inhibitor Action In Cellular Stress & Cell Death Pathways